Navigation Links
Killing brain tumors from within: A 'Trojan horse' approach

A new method for targeting malignant brain tumors through inducing the cancerous cells to "commit suicide" has been developed by a team of researchers headed by a Hebrew University of Jerusalem professor of biochemistry.

Alexander Levitzki, who is the Wolfson Family Professor of Biochemistry, his research associate, Dr. Alexei Shir, and his colleagues from the Ludwig-Maximilians University of Munich, Germany, have pioneered a technique in which a molecule containing long, double-stranded RNA is attached to epidermal growth factor (EGF) and delivered selectively to cells with an abnormally high number of epidermal growth factor receptors (EGFR).

This proliferation of EGFR is typical of certain types of cancer cells, including glioblastoma multiforme (GBM), the most lethal form of brain cancer.

The nucleic acid-EFG molecule acts as a "guided missile," explained Prof. Levitzki, which, when injected into the blood stream, is avidly gobbled up by the multiple EGF receptors on the cancer cells, without harming normal cells. Once embedded in the tumor cells, it destroys them from within ?a true "Trojan horse," said Prof. Levitzki. Normal cells, which possess 20 to100 less receptors for EGF, are spared, since the amount of double-stranded RNA gobbled up is insufficient to induce them to die.

The lethal RNA approach has been applied to mice in which human brain tumors were grown. The tests proved 100% effective in eliminating the tumorous growths.

An article on the work of Prof. Levitzki, along with his associate Dr. Shir and Professors Manfred Orgris and Ernst Wagner of Ludwig-Maximilians University in Munich, was published in a recent article in the journal PLOS Medicine.

Further testing is planned in a clinical setting. In the meantime, a small start-up company, Algen Biopharmaceuticals Ltd., has been established through the Hebrew University's Yissum Technology Transfer Company to promote commercial devel opment of the new drug. Prof. Levitzki believes that the project has great potential, especially in view of the fact that over-expression of EGF receptors is involved in over 25 % of all types of cancers. The strategy developed to combat GBM can also be applied to other types of receptors found on cancerous cells, he added.

Last year, Prof. Levitzki was named as a winner of the prestigious Wolf Prize in Medicine for his research on cancer development and treatment. His previous work has already led to successful therapy in treating leukemia and some lung cancer patients.
'"/>

Source:The Hebrew University of Jerusalem


Related biology news :

1. Duke Experiments Boost Radiations Cancer-Killing Effects
2. Killing the messenger RNA -- But which one?
3. Controversial drug shown to act on brain protein to cut alcohol use
4. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
5. Mouse brain tumors mimic those in human genetic disorder
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. First atlas of key brain genes could speed research on cancer, neurological diseases
8. NYU study reveals how brains immune system fights viral encephalitis
9. Stem cells from brain transformed to produce insulin at Stanford
10. Birds brains reveal source of songs
11. Loves all in the brain: fMRI study shows strong, lateralized reward, not sex, drive

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, ... on emerging technology, announces the availability of a new report, ... Continue Reading ... ... industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, ...
(Date:1/26/2017)... DENVER , Jan. 26, 2017  Acuity ... Trends for Biometrics and Digital Identity".  Acuity characterizes ... digital identity when increased adoption reflects a new ... "Biometrics and digital identity are ... says Maxine Most , Principal of Acuity ...
(Date:1/23/2017)...  The latest mobile market research from Acuity Market ... The quarterly average price of a biometric smartphone decreased ... 2016.  There are now 120 sub-$150 models on the ... just 28 a year ago at an average price ... Most , Acuity Market Intelligence Principal, "Biometric Smartphones are ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will be ... will be held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). ... They provide an opportunity to interact with peers, make new connections and talk bio ...
(Date:2/16/2017)... CALABASAS, Calif. , Feb. 16, 2017 /PRNewswire/ ... on developing groundbreaking therapies to treat severe neurological ... in children treated with AGT-181, the company,s investigational ... syndrome (also known as mucopolysaccharidosis type I, or ... Phase 2 proof-of-concept (POC) study, presented today at ...
(Date:2/16/2017)... 2017 Patient Care services ... telemedicine application, new and leading edge therapies and ... boom worldwide. The healthcare sector as whole continues ... and new therapies for companies such as Reliq ... Biosciences, Inc. (NASDAQ: CLRB ), Cytori ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced today the ... Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at Andrews Memorial ... physician suffering from degenerative disc disease with radiculomyelopathy, as a result of degenerative ...
Breaking Biology Technology: